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Assessment of Animal Models Minireview
for MS and Demyelinating Disease
in the Design of Rational Therapy
like paralysis, and then the animals would develop
chronic neurologic disease, with relapsing episodes of
paralysis followed by periods of clinical remission and
ultimately permanent deficits. Many animal models of
MS feature only acute attacks and recovery, a situation
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that is comparable to syndromes of acute demyelinating
disease, syndromes that are closely related to MS and
may represent initial attacks of MS that are self-con-Experimental autoimmune encephalomyelitis (EAE) is a
tained.useful model of acute demyelinating disease. Some
There are three acute demyelinating diseases affect-forms of EAE reflect chronic demyelination with exacer-
ing the CNSÐacute optic neuritis (AON), acute transversebations and remissions characteristic of multiple sclero-
myelopathy (ATM), and acute disemminated encephalo-sis (MS). The chronic models of MS reflect many of
myelitis (ADE)Ðthat appear identical both clinically andthe pathophysiologic steps in MS, including the role of
pathologically to MS during periods of exacerbation.certain adhesion molecules, the influence of T cells and
Indeed, most relapses of chronic MS resemble theseantibodies reactive to components of the myelin sheath,
three acute conditions clinically and pathologically.the participation of metalloproteases in penetrating the
There is no way to distinguish ADE, AON, and ATM fromblood±brain barrier, and the cytotoxic role of certain
a first episode of MS, and in about 25% of cases thesecytokines. One of the three therapies, approved in the
acute demyelinating syndromes culminate in recurrentUnited States, for treatment of multiple sclerosis was
episodes of inflammation in brain, optic nerve, or spinaldeveloped preclinically based on its success in treating
cord. Once the syndromes return, the illness is thenvarious models of EAE. However, the role of certain
called MS. The acute demyelinating attacks last dayscytokines in EAE is contradictory to what is seen when
to weeks, often occurring following a viral infection. AONtried experimentally in MS. Recognition of the discrep-
is manifest by a transient disturbance of vision. ATM isancies between MS and its experimental models is criti-
characterized by transient paralysis and sensory distur-cal in attempting to design rational therapies for demye-
bances in the extremities, often with bowel and bladderlinating disease.
dysfunction. ADE is distinguished by various motor andPathologic Features of MS and Demyelinating
sensory disturbances and occasionally by convulsions.Disease that Must Be Reflected
One of the first known examples of ADE occurredin Animal Models
when ªparalytic accidents,º referring to spinal cord in-MS is an inflammatory demyelinating disease of CNS
flammation leading to clinical paralysis, were noted afterwhite matter. It is the major chronic disease of white
rabies immunization. This observation served as a basismatter, affecting z350,000 individuals in North America
for the development of models of acute experimentaland about twice that number in Europe. MS is much
allergic encephalomyelitis (Stuart and Krikorian, 1928;less common in India and Asia, probably reflecting a
Rivers et al., 1935; Kabat et al., 1947). The ªparalyticgenetic predisposition to a certain genotype encoded
accidentsº were due to immunization against brain tis-by the major histocompatibility locus on chromosome
sue, used for growing the attenuated rabies virus.6, termed HLA (human leukocyte antigen). Genes in the
Once it was recognized that immunization against
HLA DRB region encode the highly polymorphic portion
brain tissue could produce paralysis and demyelination
of the molecule that presents peptides to thymic-derived
in experimental animals, models of ADE were developed
T lymphocytes in the immune system. Individuals with in monkeys at the Rockefeller Institute by Rivers. Injec-
a particular HLA type (HLA DRB1*1501, formerly known tion of a mixture of brain material with complete Freund's
as HLA DR2) are three to four times more susceptible adjuvant, an emulsion made from killed mycobacteria
to MS than individuals who have a different HLA type tuberculosis, which is useful in initiating a vigorous im-
at this locus. The incidence of MS in northern Europe, mune response, permitted the development of highly
where HLA DR2 is most common, is as high as 1 per reproducible models of acute paralysis and white matter
750 individuals. Females are affected twice as often as inflammation (Kabat et al., 1947). The efforts of Rivers,
males (Steinman, 1996). Freund, and Kabat resulted in the establishment of ani-
Approximately 85% of MS cases begin as relapsing mal models of experimentally induced autoimmunity in
remitting disease, with episodes of neurologic impair- the nervous system, termed experimental allergic en-
ment involving major white matter tracts impairing vi- cephalomyelitis (later to be interchanged with experi-
sion, other sensory modalities, motor performance, or mental autoimmune encephalomyelitis), which is abbre-
coordination. Episodes of relapse and remission often viated EAE. In the basic protocol for inducing EAE,
evolve over many years to a more chronic form of disabil- experimental animals are immunized with either foreign
ity without clear cut exacerbations. These clinical sce- or self proteins from the white matter of the nervous
narios become important in the development of animal system, most usually myelin basic protein (MBP), pro-
models of MS. The most useful animal models would teolipid protein (PLP), or myelin oligodendroglial glyco-
develop acute attacks with specific neurologic deficits protein (MOG). The acute EAE models reflect many of
the features of AON, ATM, and ADE. Unlike MS, these
illnesses occur acutely and then resolve with varying*E-mail: steinman@stanford.edu.
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degrees of residual disease in the optic nerves, spinal Table 1. Comparisons between Multiple Sclerosis and EAE
cord, or white matter of the brain. MS, in contrast to
MS EAEthese acute diseases, is chronic, lasting a lifetime, and
is commonly manifest by episodes of inflammation in the Clinical Presentation
Relapses and remissions present presentwhite matter, leading to permanent disabilities. Multiple
Paralysis present presentschemes for immunization, including innoculation with
Ataxia present presentT cell clones specific for myelin proteins and the injec-
Visual impairment present present
tion of various antigens with different combinations of Genetics
adjuvants, have been used to produce chronic relapsing MHC-linked susceptibility yes yes
EAE. These animal models of MS incorporate most of Females more susceptible yes yes
Pathology in Lesionsthe features described below.
T cells reactive to myelin present presentIn MS, evidence points to an immune response
Antibodies to myelin present presentagainst components of the myelin sheath. A widely ac-
a4 integrin, complement present presentcepted view of the process of demyelination reveals that
TNFa, gIFN present present
T cells, immunoglobulin, and complement play a role in Demyelination present present
pathogenesis. Adhesion molecules, cytokines, chemo- Axonal dystrophy present present
kines, HLA molecules, and metalloproteases are critical Therapy
gIFN, systemic worsens curesparticipants in the development of the inflammatory re-
anti-TNFa, systemic worsens curessponse in brain. Initially, circulating autoreactive myelin-
IL-4 transduced T cells not done curesspecific CD41 Th1 cells are activated in the periphery by
TNFa transduced T cells not done worsens
nonself antigens, likely to be of microbial origin. These Copaxone improves cures
microbial components resemble CNS myelin proteins, bIFN improves improves
and this resemblance between self and nonself mole-
cules is called molecular mimicry (Steinman, 1996; Con-
of mice with EAE (Steinman, 1996). Similarly, antibodylon et al., 1999). These circulating T cells, which recog-
responses to MBP and to MOG can be detected at thenize molecules resembling myelin, are captured on
site of vesiculating myelin in EAE brain (Warren et al.,vascular endothelium in the brain first by selectins and
1995; Genain et al., 1999). Immunization with variousthen by ligand±receptor interactions between integrin
myelin proteins in suitable adjuvants or with T cell clonesmolecules. T cells migrate through the endothelium in
specific for certain peptides within these proteins canresponse to chemotactic signals, and metalloprotein-
trigger chronic relapsing, demyelinating disease in ro-ases or other matrix-degrading enzymes facilitate T
dents and nonhuman primates. In EAE, T cell immunecell penetration through the basement lamina. Microglial
responses spread to different portions of a given myelincells and astrocytes reactivate T cells locally in the CNS
protein and then spread to various myelin antigens, aby presentation of myelin antigens complexed with ma-
phenomenon known as ªantigen spreading.º Immuniza-jor histocompatibility complex class II molecules. T cells
tion with microbial sequences resembling myelin anti-stimulate macrophages by secretion of inflammatory
gens can either induce clinical paralysis and demyelin-cytokines, and macrophages in turn show increased
ation or protect against disease in EAE (Conlon et al.,phagocytic activity and release free oxygen radicals,
1999). This is often interpreted to mean that the microbe,nitric oxide metabolites, proteases, arachidonic acid de-
toward which the immune response is directed, actuallyrivatives, and complement components that damage
triggered the disease (Wucherpfennig et al., 1997). Fi-myelin. Autoantibodies against myelin antigens, such
nally, in chronic relapsing EAE, there is also evidenceas myelin basic protein and myelin oligodendroglial gly-
for axonal pathology (Raine and Cross, 1988).coprotein, also have an important role in demyelination
Experimental Encephalomyelitis as a Preclinical(Warren et al., 1995; Wucherpfennig et al., 1997; Genain
Proving Ground for MS Therapeutics:et al., 1999). In addition to myelin damage, there is clear
Successes and Problemsevidence in MS for axonal loss and dysfunction (Trapp
Molecules that can be detected in inflammatory MS le-et al., 1998). Many of these gene products involved in
sionsÐa4 integrin, matrix metalloproteases, and the cy-this scenario for the pathogenesis of MS have been
tokines interleukin-6 (IL-6), tumor necrosis factor ademonstrated at the sites of lesions by standard meth-
(TNFa), and g interferon (g-IFN)Ðas well as CD41 T cellsods of immunohistochemistry, in situ hybridization, and
reactive to myelin proteins, can also be demonstratedreverse transcriptase±based PCR.
in inflamed brain and spinal cord in EAE. TreatmentsExperimental Autoimmune Encephalomyelitis
Chronic relapsing EAE reflects many of the features seen with antibodies to a4 integrin, to CD41 T cells reactive
to myelin proteins, and to the cytokines IL-6 and TNFain MS (Table 1). Females, who are twice as susceptible
to MS as males, are overwhelmingly more susceptible have all reversed paralysis in various models of EAE.
Likewise, administration of small molecule metallopro-to EAE induction in mice. Susceptibility to EAE in mice
is closely linked to loci in the major histocompatibility tease inhibitors and altered peptide ligands (APLs) for
T cell receptors recognizing myelin antigens have alsocomplex that are comparable with HLA in humans. T
cell and antibody responses to various myelin proteins, reversed EAE (Conlon et al., 1999). This has lead to
clinical trials targeting a4 integrin, CD4, T cells reactivelike myelin basic protein, myelin oligodendroglia glyco-
protein, and proteolipid protein, can be detected in the to myelin antigens, TNFa, and g-IFN. Many of these
approaches are being tested in phase II clinical trials,cerebrospinal fluid of animals with EAE. T cell receptor
rearrangements indicative of T cells reactive to myelin where dose and timing of administration of the therapeu-
tic agent are ascertained. To date, the most promisingcan even be detected in demyelinating areas from brains
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therapeutic approach to come out of the EAE model is be the key inflammatory mediator in EAE or MS is an
Copaxone, a synthetic polymer analog of MBP, which open question. Some resolution of this issue has been
has been successful in reducing the relapse rate in MS addressed with mice in which TNF family membersÐ
in clinical trials and is currently approved for treatment either TNFa, LT, or bothÐare disrupted.
of MS (Arnon, 1996). TNFa, LT, and other members of the TNF family may
b interferon (b-IFN), approved for use in the United play a key role in the pathogenesis of oligodendroglial
States and the EEU for treatment of relapsing MS, was damage. In vitro, TNFa can damage myelin and injure
originally tried as an antiviral compound for treatment oligodendrocytes in culture (Selmaj and Raine, 1988). In
of MS, a disease often linked to a viral etiology. After various models of EAE, blockade of TNFa with mono-
b-IFN was proved to be effective clinically in relapsing clonal antibodies or soluble TNFa receptor constructs
remitting MS, it was shown that recombinant b-IFN can prevent or reverse disease. Therapy with altered
could ameliorate EAE, though severe relapses were peptide analogs of MBP, which downregulate the ex-
seen when b-IFN was discontinued (Ruuls et al., 1996). pression of TNFa, reverses EAE even after paralysis is
Immunologists have divided T cell responses into two apparent (Steinman, 1996). Downregulation of TNFa by
categories, based on the types of cytokines T cells pro- phosphodiesterase IV inhibitors prevents and reverses
duce after stimulation: Th1 responses, commonly found EAE as well. Overexpression of TNFa in the CNS in
in T cells from individuals with organ-specific autoim- transgenic mice leads to spontaneous inflammatory de-
mune diseases like MS or rheumatoid arthritis, lead to myelinating disease (Conlon et al., 1999).
production of g-IFN and TNFa, while Th2 responses, Targeted gene deletion in mice of LTa alone, with
commonly found in T cells from individuals with allergic TNFa expression left intact, blocks the development of
conditions or parasitic infections, are characterized by EAE (Conlon et al., 1999). This indicates, at least in ro-
the release of IL-4, IL-5, and IL-10. MS is considered a dent models of demyelination, that LTa may play the
Th1-type autoimmune disease, as is EAE. However, EAE decisive role in demyelination, rather than TNFa. In con-
can be induced with Th2-type T cell clones (Lafaille trast, in mice with the TNFa gene deleted, there is never-
et al., 1997), demonstrating that other cytokines can theless intense inflammation in the CNS. Mice deficient
assume critical functions in producing the phenotype in TNFa develop a more severe form of EAE. EAE in
characteristic of EAE. Clearly, there is a great deal of these TNFa knockout mice can be ameliorated by ad-
redundancy in the immune response. Although experi- ministering TNFa (Liu et al., 1998).
mental autoimmune encephalomyelitis and experimen- Thus, it is unclear from various EAE models whether
tal allergic encephalomyelitis are used interchangeably, TNFa is a pathologic player and should be inhibited, or
perhaps it is time to refer to disease caused via Th1 whether it might indeed have protective effects. When
clones as ªexperimental autoimmune encephalomyeli- myelin-specific T cells transduced with retroviruses car-
tis,º while disease induced by Th2 clones could be re- rying cytokines have been given to mice with EAE, IL-
ferred to as ªexperimental allergic encephalomyelitis.º 4-transduced T cells ameliorated EAE, while TNFa-
It is clear that two of the critical cytokines involved in transduced cells worsened disease. When targeting is
the pathogenesis of MS are g-IFN and TNFa. A clinical more precise, using retrovirally transduced myelin-spe-
trial was performed in the 1980s to test the efficacy of cific T cells that can home to the site of disease, a Th1
g-IFN in MS. Results showed that g-IFN exacerbated cytokine exacerbated and a Th2 cytokine ameliorated
disease, and the trial was halted while in progress (Pan- EAE (Dal Canto et al., 1999). The effects of cytokines
itch et al., 1987). The results implied that g-IFN is patho- and their inhibitors when given systemically, or when
genic in MS. Paradoxically, in EAE systemic administra- their genes have been disrupted globally, may be para-
tion of g-IFN protects from paralysis (Krakowski and doxical, especially when interpreting results with poten-
Owens, 1996). tial therapeutics such as monoclonal antibodies or solu-
Another cytokine believed to play a key role in MS is
ble receptors that are unable to penetrate to the site of
TNFa. This is based on the observation that there is an
disease across the blood±brain barrier.
increase in TNFa in the cerebrospinal fluid preceding
Though EAE has many features that reflect what isand during relapses of disease (Sharief and Hentges,
known about the pathophysiology of MS, there are many1991). However, thus far in humans, treatments with
discrepancies between the pathology of EAE and MS.monoclonal anti-TNF antibody and soluble TNF receptor
Therefore, extrapolations must be made with cautionhave actually worsened MS (van Osten et al., 1996).
when predicting what might happen in MS, based onThe anti-TNF treatments that failed in MS have been
results obtained in the EAE model. Results of ongoingsuccessful in other diseases like rheumatoid arthritis
clinical trials targeting a4 integrin with humanized anti-and Crohn's Disease, where TNFa plays a critical role.
bodies, metalloproteases with small molecule inhibitors,Clinical trials with reagents that block TNFa in the pe-
and T cells reactive to myelin antigens with humanizedriphery have exacerbated MS, but therapeutic trials with
antibodies and altered peptide ligands should allow usphosphodiesterase inhibitors and other approaches like
to judge the utility of EAE as a model to predict therapeu-altered peptide ligands that can downregulate TNFa
tic efficacy for MS. So far, the development of the ap-within the CNS have not been reported as yet.
proved MS drug, Copaxone, based on its efficacy inThe discrepancies between the results with inhibition
EAE and the success of b-IFN in treating EAE must beof TNFa in EAE versus MS are quite perplexing. TNFa
balanced with the failures of anti-TNFa and g-IFN in MS,and lymphotoxin (LT) are members of the TNF family of
after their successful use in various models of EAE. Itcytokines, and although they have different structures
is too early to judge whether amelioration of EAE willthey both bind to the same receptors and produce simi-
lar biologic effects. Whether it is TNFa or LT that may be a reliable predictor of success in treating MS.
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